Our masked, IgG1 FC-engineered anti-CD137 POWERbody™ combines conditional activation in the tumor microenvironment with strong agonistic activity through heightened FcγR-mediated crosslinking for therapeutic potential in either single agent or combination regimens.
Preclinical data demonstrated that ADG206 was well tolerated and had robust anti-tumor activity as a single agent in multiple tumor models, with 4-fold stronger anti-CD137 agonistic activity of its activated form than a benchmark antibody in development (analog of urelumab) for T cell co-activation. ADG206 also demonstrated enhanced anti-tumor activity in combination with other checkpoint inhibitors, including anti-PD-1 or anti-CTLA-4 therapy.
A phase 1 trial is ongoing to evaluate the safety, efficacy and tolerability profiles for ADG206 in patients with advanced/metastatic tumors. This next generation anti-CD137 candidate is the first POWERbody candidate to advance into clinic, combining precision masking, Fc-engineering and targeting of a unique epitope to solve the safety and efficacy challenges of anti-CD137 therapies.